Orchestra BioMed(OBIO.US)

Company Encyclopedia
View More
name
Orchestra BioMed
OBIO.US
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
1.378 T
OBIO.USMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
D
Health Care EquipmentIndustry
Industry Ranking121/175
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-166.97%E
    • Profit Margin-2665.05%E
    • Gross Margin94.31%A
  • Growth ScoreC
    • Revenue YoY6.46%C
    • Net Profit YoY-30.19%D
    • Total Assets YoY39.15%A
    • Net Assets YoY-5.37%D
  • Cash ScoreC
    • Cash Flow Margin-3.75%D
    • OCF YoY6.46%C
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreD
    • Gearing Ratio58.27%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chmn Hochman Surrenders 43,638 Of Orchestra BioMed Holdings Inc [OBIO]

    David P. Hochman, Chairman of Orchestra BioMed Holdings Inc, surrendered 43,638 shares back to the company to cover option exercise costs and tax liabilities. The transaction was disclosed in a Form 4 filed with the SEC on December 12, 2025. Hochman's ending holdings are 1,021,089 shares, with 572,467 held directly and 448,622 indirectly.

    Reuters·
    US
    OBIO
    +0.24%
    Reuters·
    US
    OBIO
    +0.24%

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts

    Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received a 'Moderate Buy' rating from six analysts. The stock's average 1-year target price is $13.25. Recent analyst reports show mixed ratings, with some downgrades in price objectives. Institutional investors have adjusted their stakes, and the stock is currently valued at $4.39. The company reported a quarterly loss, missing earnings estimates, with a negative return on equity and net margin. Orchestra BioMed focuses on biomedical innovations, including therapies for hypertension and artery disease.

    Market Beat·
    US
    OBIO
    +0.24%
    Market Beat·
    US
    OBIO
    +0.24%

    Orchestra BioMed Showcases AVIM Therapy and Virtue SAB at ICI Meeting

    Orchestra BioMed Holdings Inc. showcased its AVIM Therapy and Virtue SAB at the 2025 Innovation in Cardiology Intervention meeting in Tel Aviv. The company presented on its collaboration with Medtronic for hypertension treatment in pacemaker patients and highlighted the Virtue SAB's drug delivery technology for coronary artery disease. The news was originally published by Orchestra Biomed via GlobeNewswire.

    Reuters·
    US
    OBIO
    +0.24%
    Reuters·
    US
    OBIO
    +0.24%

    Orchestra BioMed Grants Stock Options to New Hires Under Inducement Plan

    Orchestra BioMed Holdings Inc. has granted stock options for 151,250 shares to 12 new employees under its 2025 New Hire Inducement Plan. The options vest 25% after one year, with the remainder vesting quarterly over three years. This announcement was originally published by Orchestra BioMed via GlobeNewswire.

    Reuters·
    US
    OBIO
    +0.24%
    Reuters·
    US
    OBIO
    +0.24%

    Orchestra BioMed Director and Officer David P. Hochman Reports Acquisition of Common Shares

    David P. Hochman, Director and Officer of Orchestra Biomed Holdings Inc., reported acquiring common shares of the company. This information was published via EDGAR by the U.S. Securities and Exchange Commission on November 17, 2025. The news is for informational purposes and not financial advice.

    Reuters·
    US
    OBIO
    +0.24%
    Reuters·
    US
    OBIO
    +0.24%
    © 2026 Longbridge｜Disclaimer